Protalix BioTherapeutics (PLX) Inventory (2010 - 2026)

Protalix BioTherapeutics has reported Inventory for 17 years, with the latest figure at $32.3 million in Q2 2026.

• On a quarterly basis, Inventory rose 52.82% year-over-year to $32.3 million in Q2 2026; TTM through Jun 2026 was $32.3 million, a 52.82% increase from a year earlier, with the FY2025 full-year figure at $25.7 million, up 21.12% from the prior year.
• Inventory was $32.3 million for Q2 2026 at Protalix BioTherapeutics, up from $30.5 million in the prior quarter.
• The five-year high for Inventory was $32.3 million in Q2 2026, with the low at $14.6 million in Q3 2022.
• Average Inventory over 5 years is $20.9 million, with a median of $20.5 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: Inventory decreased 20.31% in 2024, then soared 56.23% in 2026.
• Over 5 years, Inventory stood at $16.8 million in 2022, then grew by 13.34% to $19.0 million in 2023, then grew by 11.54% to $21.2 million in 2024, then grew by 21.12% to $25.7 million in 2025, then increased by 25.51% to $32.3 million in 2026.
• The last three Inventory figures came in at $32.3 million (Q2 2026), $30.5 million (Q1 2026), and $25.7 million (Q4 2025), per Business Quant data.